Why You Might Be Losing Weight Slowly on Mounjaro

Is slow weight loss in the first few weeks on Mounjaro normal?

Almost always, yes. A question our prescribers hear most weeks is whether something has gone wrong because the scales barely moved during the first pen. The honest answer is that the starter dose exists specifically to settle your system, not to produce rapid results. Your body needs time to adapt to tirzepatide, and the titration schedule (moving through doses roughly every four weeks) is deliberately gradual for that reason.

The NHS tirzepatide page confirms that treatment begins at 2.5mg before being increased by the prescriber in stages. At that opening dose, appetite suppression is modest for many people. Gastrointestinal side effects, if they occur, can also temporarily affect food intake in unpredictable ways, sometimes eating less than planned, sometimes eating more to manage nausea. Neither is a reliable signal of what longer-term progress will look like.

The SURMOUNT-1 trial, which involved around 2,500 adults with obesity, found average body-weight reductions of roughly 20–21% at the 15mg dose over 72 weeks, but those results accumulated progressively across the full treatment period, not in the opening month. Comparing your week-six progress against a 72-week average will almost always feel discouraging, and usually unfairly so. For a broader clinical overview of how tirzepatide works, the Medscape reference on tirzepatide provides a detailed summary of the pharmacology and evidence base. For a broader picture of how weight loss typically unfolds over the course of treatment, the page on losing weight on Mounjaro sets out what most people experience at each stage.

What else might be slowing progress beyond the dose?

Mounjaro reduces appetite, but it does not override the rest of your physiology. Several factors can put a ceiling on how quickly the medicine translates into weight change, and identifying them is more useful than concluding the treatment has stopped working.

Calorie intake is the most obvious place to look, but not always in the way people assume. When appetite falls sharply, some people eat very little and then find energy levels drop, making activity harder. A prescriber or dietitian might suggest prioritising protein and staying adequately hydrated rather than simply eating less. Sleep deprivation and chronic stress both affect cortisol and hunger hormones in ways that partially counteract appetite suppression. Underlying conditions, including underactive thyroid or polycystic ovary syndrome, can independently slow weight loss and may need separate management.

Medication interactions are another consideration. Certain medicines affect weight independently, and some affect absorption. If you take oral contraceptives alongside tirzepatide, NHS England's guidance on weight-management injections advises adding a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying may reduce how reliably the pill is absorbed. That same mechanism can, in some people, affect how efficiently other oral medicines work during the early weeks. Always raise any concerns about existing medication with your prescriber rather than adjusting things yourself.

Does hitting a plateau mean Mounjaro is no longer working?

A plateau is a normal part of the weight-loss process, on or off medication. After several months, the body adapts: resting metabolic rate tends to fall as weight decreases, which means the same calorie deficit produces less change than it did at the start. This is biology, not a treatment failure.

The relevant clinical benchmark is set out in NICE's appraisal of tirzepatide (TA1026): if weight loss is below 5% after six months at the highest dose the person can tolerate, continuing is reviewed. That threshold is about identifying the small proportion of people who genuinely do not respond to tirzepatide, not about judging early or mid-treatment progress against a fixed schedule.

If you have reached a higher dose and progress has stalled for several weeks, the most productive step is a clinical conversation. A prescriber can look at the full picture: current dose, dietary patterns, activity, any contributing conditions and whether there is scope to move to the next dose level. The page on what to do when you stop losing weight on Mounjaro covers practical steps in more detail, and the factors behind slow Mounjaro weight loss goes deeper into the physiology. There is also useful context on when weight loss typically slows during treatment and what that pattern usually means.

When should you speak to your prescriber rather than waiting it out?

Patience is usually the right first instinct, but there are situations where it is better to get in touch sooner. If nausea, vomiting or diarrhoea have been severe enough to prevent you eating or drinking normally for more than a day or two, that is worth flagging, not least because dehydration can affect kidney function. If you have developed new or persistent abdominal pain that radiates towards the back, seek urgent medical advice; this is one of the warning signs associated with pancreatitis, which the MHRA highlighted in a safety update in January 2026 as a known but uncommon side effect of GLP-1 medicines.

Beyond urgent safety questions, a routine check-in with your prescriber is the right route if you feel your progress has genuinely stalled at a dose you have been on for eight weeks or more. Dose titration, dietary adjustments and investigation of any contributing conditions are all things a prescriber can help with. At nume, our clinical team reviews every repeat prescription individually, there is no automated sign-off. If slow progress is something you want to explore properly, the most direct step is to start a free consultation so a GPhC-registered prescriber can look at your situation specifically. You can also read more about the wider context of weight-loss treatment options or learn about tirzepatide as a medicine in more depth.